الفهرس 
introductionOnly 14 pages are availabe for public view
 |  | from | 107 |  |  |
| | | from | 107 | | |
Abstract
In this study we investigated the expression of cyclin D1 in group of NHL patient and correlated the results with the clinical and laboratory data to assess the role of cyclin D1 in NHL patient. The degree of expression of cyclin D1 protein was evaluated by flowcytometry in a group of NHL patients (23) and in normal control group (10). Cyclin D1 was over expressed in (21.7%) of the total NHL patients (5/23) [(3/3) MCL 100% and (2/5) large B-cell lymphoma 13.4%]. All other NHL subtypes showed normal cyclin D1 expression (follicular, small B-cell, anablastic and lymphoblastic lymphoma). The clinical (hepatomegaly, splenomegaly and B-symptoms) and laboratory data (Hb, WBCs, platelet count, differential leucoytic count, LDH, ESR, bone marrow infiltration) were not significantly different between NHL subgroups: those with cyclin D1 over expression and the other with normal cyclin D1 expression. In conclusion, our results showed that cyclin D1 over expression was evident among all cases of MCL and few cases of large B-cell lymphoma. Therefore, cyclin D1 over expression might: 1) Be used as adjuvant tool for diagnosis of MCL. 2) Has role in NHL biology. 3) Correlate to NHL variants with adverse outcome (Mantle cell, diffuse large B-cell).